259 related articles for article (PubMed ID: 26412341)
21. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
[TBL] [Abstract][Full Text] [Related]
22. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
Takeda A; Kunieda E; Ohashi T; Aoki Y; Oku Y; Enomoto T; Nomura K; Sugiura M
Chest; 2012 Apr; 141(4):858-866. PubMed ID: 21885726
[TBL] [Abstract][Full Text] [Related]
23. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy.
Borst GR; Ishikawa M; Nijkamp J; Hauptmann M; Shirato H; Onimaru R; van den Heuvel MM; Belderbos J; Lebesque JV; Sonke JJ
Radiother Oncol; 2009 Jun; 91(3):307-13. PubMed ID: 19321217
[TBL] [Abstract][Full Text] [Related]
24. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.
Baker R; Han G; Sarangkasiri S; DeMarco M; Turke C; Stevens CW; Dilling TJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):190-5. PubMed ID: 22929858
[TBL] [Abstract][Full Text] [Related]
25. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
[TBL] [Abstract][Full Text] [Related]
26. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
[TBL] [Abstract][Full Text] [Related]
27. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Koshy M; Malik R; Weichselbaum RR; Sher DJ
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
[TBL] [Abstract][Full Text] [Related]
28. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis.
Yamaguchi S; Ohguri T; Ide S; Aoki T; Imada H; Yahara K; Narisada H; Korogi Y
Lung Cancer; 2013 Nov; 82(2):260-5. PubMed ID: 24054547
[TBL] [Abstract][Full Text] [Related]
30. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.
Parks J; Kloecker G; Woo S; Dunlap NE
Am J Clin Oncol; 2016 Apr; 39(2):147-53. PubMed ID: 24457534
[TBL] [Abstract][Full Text] [Related]
32. Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.
Okubo M; Itonaga T; Saito T; Shiraishi S; Mikami R; Nakayama H; Sakurada A; Sugahara S; Koizumi K; Tokuuye K
Br J Radiol; 2017 May; 90(1073):20160508. PubMed ID: 28195507
[TBL] [Abstract][Full Text] [Related]
33. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.
Ueyama T; Arimura T; Takumi K; Nakamura F; Higashi R; Ito S; Fukukura Y; Umanodan T; Nakajo M; Koriyama C; Yoshiura T
Br J Radiol; 2018 Jun; 91(1086):20170453. PubMed ID: 29565649
[TBL] [Abstract][Full Text] [Related]
35. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.
Kim TH; Cho KH; Pyo HR; Lee JS; Zo JI; Lee DH; Lee JM; Kim HY; Hwangbo B; Park SY; Kim JY; Shin KH; Kim DY
Radiology; 2005 Apr; 235(1):208-15. PubMed ID: 15703313
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiotherapy in patients with previous pneumonectomy: safety and efficacy.
Thompson R; Giuliani M; Yap ML; Atallah S; Le LW; Sun A; Brade A; Cho BC; Bezjak A; Hope A
J Thorac Oncol; 2014 Jun; 9(6):843-7. PubMed ID: 24828663
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer.
Liu Y; Wang W; Shiue K; Yao H; Cerra-Franco A; Shapiro RH; Huang KC; Vile D; Langer M; Watson G; Bartlett G; Ai H; Sheski F; Jin JY; Zellars R; Fu P; Lautenschlaeger T; Kong FS
Radiother Oncol; 2021 Mar; 156():231-238. PubMed ID: 33096168
[TBL] [Abstract][Full Text] [Related]
38. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
[TBL] [Abstract][Full Text] [Related]
39. Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Muller DA; Dutta SW; Aliotta E; Sanders JC; Wijesooriya K; Watkins WT; Larner JM
Clin Lung Cancer; 2021 May; 22(3):234-241. PubMed ID: 32690439
[TBL] [Abstract][Full Text] [Related]
40. Radiological changes after stereotactic radiotherapy for stage I lung cancer.
Dahele M; Palma D; Lagerwaard F; Slotman B; Senan S
J Thorac Oncol; 2011 Jul; 6(7):1221-8. PubMed ID: 21623237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
